01 January 2009
Plasma complement 3d levels in the early phase after pancreas transplantation
Angela Suermann, Oliver Vonend, Peter Schenker, Richard Viebahn, Lars C. Rump, Stefan M. WeinerAnn Transplant 2009; 14(3): 29-35 :: ID: 880538
Abstract
Background: Rejection and graft thrombosis are the main reasons leading to early graft loss after pancreas transplantation. Identifying parameters that forecast these complications would be helpful. Complement activation might occur during rejection and thrombosis leading to elevated complement split products. This prospective study analyses the plasma complement 3d (C3d) levels in the early post-pancreas transplant (PTx) period to test its predictive value to determine rejection and thrombosis.
Material/Methods: Plasma C3d levels were measured after isolated PTx (n=2), simultaneous pancreas and kidney transplantation (SPKT, n=20) and pancreas re-transplantation (n=3).
Results: Pancreas rejection was observed in 3, pancreas thrombosis in 4, and kidney rejection in 7 patients. Patients after isolated kidney transplantation (IKT) served as controls. Within 40 days after PTx and IKT C3d levels were significantly elevated compared to volunteers and long-term kidney transplant recipients (p<0.001). C3d levels increased during 40 days after PTx, but dropped after IKT. During pancreas rejection episodes mean C3d levels were elevated (14.0±3.5 mg/l) compared to those obtained during graft thrombosis (9.1±1.6 mg/l; p=0.012) or periods of normal graft function (10.6±1.9 mg/l; p=0.046). A slight elevation of C3d was observed during kidney rejection episodes in SPKT (12.7±2.0 mg/l; p=0.074) but not during kidney rejection after IKT.
Conclusions: C3d plasma levels increase during episodes of pancreas rejection and decrease in pancreas transplant thrombosis. However, single C3d values have no predictive diagnostic value after SPKT.
Keywords: Complement 3d
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






